Aptabio Therapeutics (XKRX:293780) Days Sales Outstanding : 70.93 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics Days Sales Outstanding?

Aptabio Therapeutics's average Accounts Receivable for the three months ended in Mar. 2024 was ₩495.3 Mil. Aptabio Therapeutics's Revenue for the three months ended in Mar. 2024 was ₩637.2 Mil. Hence, Aptabio Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2024 was 70.93.

The historical rank and industry rank for Aptabio Therapeutics's Days Sales Outstanding or its related term are showing as below:

XKRX:293780' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.63 Med: 1.98 Max: 96.69
Current: 96.69

During the past 7 years, Aptabio Therapeutics's highest Days Sales Outstanding was 96.69. The lowest was 1.63. And the median was 1.98.

XKRX:293780's Days Sales Outstanding is ranked worse than
70.87% of 999 companies
in the Drug Manufacturers industry
Industry Median: 71.45 vs XKRX:293780: 96.69

Aptabio Therapeutics's Days Sales Outstanding increased from Mar. 2023 (16.48) to Mar. 2024 (70.93).

Aptabio Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Aptabio Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics Days Sales Outstanding Chart

Aptabio Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

2.32

Aptabio Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															16.48	47.35	-	-	70.93

Competitive Comparison of Aptabio Therapeutics's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Aptabio Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptabio Therapeutics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aptabio Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Aptabio Therapeutics's Days Sales Outstanding falls into.

Aptabio Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Aptabio Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	323.869	*	365
=	0					/	323.869	*	365
=	0.00

Aptabio Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (0	+	495.337)	/	1 )	/	637.232	*	365 / 4
=	495.337					/	637.232	*	365 / 4
=	70.93

Aptabio Therapeutics (XKRX:293780) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Aptabio Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptabio Therapeutics (XKRX:293780) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » Days Sales Outstanding

Traded in Other Exchanges

N/A

Address

13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954

Website

http://www.aptabio.com

Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics (XKRX:293780) Headlines

No Headlines